We are doing this research to identify biomarkers in individuals who are at-risk for familial prion disease. We hope to use these biomarkers to predict timing of disease onset in pre-symptomatic individuals and to guide the direction of future clinical trials.
This study aims to measure biomarkers longitudinally in individuals at risk of developing genetic prion disease to identify clinical assays and molecular markers that: can inform our understanding of pre-clinical pathology, predict timing of disease onset in pre-symptomatic individuals, and enable development and evaluation of novel treatment efficacy in pre-symptomatic or early symptomatic individuals. Participation in the study involves annual visits to the clinic site in Charlestown, MA. Study visits include: a medical exam, blood draws, cognitive tests and questionnaires, spinal fluid collection, and (optional) MRI. Travel support and stipend is provided for interested individuals.
Study Type
OBSERVATIONAL
Enrollment
150
Alzheimer's Clinical and Translational Research Unit
Charlestown, Massachusetts, United States
RECRUITINGCSF YKL40
Levels of YKL40
Time frame: 1 year
CSF Tau
Levels of Tau
Time frame: 1 year
CSF Nfl
Levels of Nfl
Time frame: 1 year
CSF GFAP
Levels of GFAP
Time frame: 1 year
CSF Prion protein
Levels of Prion protein
Time frame: 1 year
CSF Prion biomarkers
RT-QuIC levels
Time frame: 1 year
Cognition
NIH Toolbox measures of cognition
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.